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Diabetic retinopathy (DR) is the most common compli-
cation of diabetes and remains a major cause of pre-
ventable blindness. Anatomical and functional changes occur
in various retinal cells including retinal endothelial cells,
neurons, and retinal pigment epithelium prior to clinical
symptoms of the disease. Early changes include appearance of
microaneurysms, leukocyte adhesion, apoptosis of vascular
(endothelial cells and pericytes), and neuronal cells. The
changes progress to involve breakdown of the inner and
outer blood retinal barriers causing diabetic macular edema,
the most leading cause of vision loss in DR. Capillary
degeneration and development of acellular capillaries lead
to impairment of retinal perfusion and subsequent hypoxia
and retinal neovascularization, the hallmark of proliferative
diabetic retinopathy (PDR). There are several therapeutic
strategies to manage the DR including laser photocoagu-
lation, anti-VEGF, and triamcinolone intraocular injection.
These therapeutic interventions are still limited by significant
side effects. Therefore, there is still an urgent need to find
out new therapies to limit the diminution or loss of vision
in diabetic patients. The current special issue through a
number of investigators and experts in the field of DR
presents both research and review articles that highlight novel
pathways implicated in the development ofDRand review the
pathophysiology and management of DR.
Novel Mechanisms of Diabetic Retinopathy. Effective thera-
peutic approaches to restore sight in diabetic patients with
clinically identifiable retinopathy are still lacking and in this
issue S. Z. Safi et al. provide a timely review of current
thinking in field. Firstly, using several scientific databases
(PubMed, Ovid MEDLINE, SPORTDiscus, and EMBASE
databases) they have reviewed the literature focusing on
the molecular mechanisms involved in the pathogenesis of
DR and, secondly on emerging strategies under consider-
ation for development of future pharmacological interven-
tions. Initially, they described the major pathways widely
recognized to be involved in disease, namely, the polyol
pathway, activation of protein kinase C (KPC) isoforms,
increased hexosamine pathway flux and increased advanced
glycation end-product (AGE) formation, and oxidative stress
along with several other mechanisms such as the potential
role of the renin-angiotensin system which are less well
researched. Arising from this discussion they summarized
established preventive measures including general, primary,
and secondary preventive strategies before covering novel
and emerging therapeutic targets such as PKC inhibitors,
VEGF inhibitors, and ACE inhibitors and drugs such as
antioxidants. Finally, the authors draw on current evidence
and clinical studies arguing for the use of fenofibrate in
halting disease progression. This review, therefore, provides
background and context for the research articles included in
this special issue.
Reactive oxygen species (ROS) generated from mito-
chondria, NADPH oxidase, and other oxidases are known
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to play an essential role in the pathogenesis of DR ROS
modify redox sensitive kinases and transcription factors such
as NF-𝜅B, Signal Transducers andActivators of Transcription
proteins (STAT), and activator protein 1 (AP-1) and therefore
induce inflammatory gene expression in DR. Alternatively,
lipid peroxidation and DNA damage induced by ROS cause
cell death in DR. In this issue, R. Liu et al. discovered
an alternative mechanism on how ROS may play a role in
DR. Using human endothelial cells (ECs), they found that
ROS treatment induces EC senescence. With gain-and-loss
function approaches, they provided the first evidence that
ROS-induced EC senescence is at least partially mediated
by downregulation of Sirtuin 6 (Sirt6), H3K9, and H3K56
deacetylase recently recognized as a novel antiaging and
anti-inflammatory molecule. Further, they found that Sirt6
antagonizes ROS-induced activation of senescence pathways,
such as p21 overexpression and activation of retinoblastoma
(Rb) protein. As accelerated aging is currently recognized as
one of the key mechanisms of many cardiovascular diseases
including DR, this study may lead to a hot area to explore
Sirtuins as well as other antiagingmolecules in DR. Certainly,
the role of Sirt6 in diabetic animals and patients remains
to be further elucidated. Increased H3K9 acetylation has
been found in DR as well as other inflammatory conditions,
suggesting that loss of Sirt6 protein and/or function is very
likely involved in DR. A challenge to directly address the
role of Sirt6 in DR is the lack of transgenic animals. Global
Sirt6 knockoutmice die within 1month and EC-specific Sirt6
knockout mice will be important to test whether lack of Sirt6
will accelerate diabetes-induced retinal vascular alterations
such as permeability and capillary degeneration if these mice
are viable.
There is now much evidence to indicate the involvement
of a dysregulated inflammatory response in early disease and
defining this role further is likely to offer exciting new avenues
for therapeutic intervention. To this end, S. Fulzele et al.
have focused on characterizing the regulation of adenosine
deaminase 2 (ADA2) by miR-146-3p. They show that the
predicted miR-146-3p target site in the UTR of ADA2 is
indeed functional. In addition, since the expression of this
microRNA is inversely related to ADA2 levels in samples
from diabetic patients and similarly treated in vitro modes
the authors conclude that miR-146-3p has a regulatory role in
diabetes related inflammation.
Most of the research on the pathogenesis of DR has
primarily focused on the injury of the neuroretina and
the dysfunction of the inner blood retinal barrier (BRB).
Contrary, the impact of diabetes on the function of retina
pigment epithelium (RPE) has received less attention and
also the underlying mechanism for RPE dysfunction during
diabetes remains unclear. The paper by S. Beasley et al.
demonstrated for the first time the important role of caspase-
14 in the development of diabeticmacular edema (DME).The
expression of caspase-14 in cultured retinal pigment epithelial
cells (ARPE-19) is correlated with the disruption of RPE bar-
rier function and hyperpermeability. In addition, knocking
down the caspase-14 in RPE abrogated the hyperglycemia-
induced RPE hyperpermeability. Interestingly, this paper also
demonstrated that caspase-14 might play a role upstream
from other caspases to mediate inflammatory and apoptotic
responses. In conclusion, this paper suggests caspase-14 as a
novel player as well as therapeutic target in DR.
Biomarkers of Diabetic Retinopathy. Diabetic retinopathy is a
progressive disease, which is clinically identifiable only at an
advanced stage; therefore markers that indicate early disease
status would be of major benefit in managing disease pro-
gression. Since there are early subclinical changes occurring
in retina prior to clinical symptoms, it is necessary to find
out specific early biomarkers that predict the pattern and
progress of these changes to an advanced stage of DR. The
discovery of biomarkers to aid in the identification of patients
most likely to develop severe DME and PDR is essential for
better treatment of this disease. In support of this concept,
B. A. Mysona et al. presented here an interesting clinical
study in which they tested whether changes in proNGF/NGF
levels observed in vitreous will be matched in serum and
thus provide rationale to examine proNGF as a biomarker
for DR. This study included analysis of serum and vitreous
samples from nondiabetic patients and patients with PDR.
Interestingly, the proNGF/NGF imbalance in serum was
comparable to the imbalance of proNGF/NGF in vitreous of
patients with PDR suggesting that serum proNGF/NGF ratio
might act as a novel biomarker that reflects the progress of
DR.
Increasing evidence indicates that inflammation is a key
player in DR. Increases in vitreous inflammatory cytokines
such as IL-6, VEGF, MCP-1, and IP-10 have been found
to be positively associated with the progression of DR and
the severity of macular edema. However, it is difficult to
get vitreous samples and therefore the feasibility of using
vitreous cytokines as biomarker is very low. In this issue,
N. Dong et al. analyzed an array of inflammatory cytokines
in the aqueous humor in relation to macular edema in
diabetic patients following uncomplicated phacoemulsifica-
tion cataract surgery. They found that concentrations of
inflammatory cytokines such as IL-1𝛽, IL-6, IL-8, MCP-
1, IP-10, and VEGF are positively associated with macular
edema whereas levels of anti-inflammatory cytokines such
as IL-10 and IL-12 are negatively associated with macular
edema. Given that it is easy to obtain the aqueous humor,
this study highlights the possibility to use these cytokines
as biomarkers for diabetic macular edema. Certainly, it is
much easier to obtain tears than aqueous humor; it would be
interesting to further explore whether there is an association
of tear inflammatory cytokines with diabetic macular edema
and neovascularization. This study also brings an interesting
question about where these inflammatory cytokines are
generated. Are they diffusing into aqueous humor or are
they generated from cells in ciliary body or cornea? Further
exploration of their source will help to better understand the
development of DR.
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